Social networks
921Activities
Technologies
Entity types
Location
1 Rue Aronnax, 44800 Saint-Herblain, France
Saint-Herblain
France
Employees
Scale: 11-50
Estimated: 16
SIREN
433988961Engaged catalyst
2Added in Motherbase
4 years, 4 months agoReliable partner for reliable molecules
Chelatec is a client oriented Contract Research Organization (CRO) specializing in radioactive labelling and preclinical investigations.
Our mission is to assist the pharmaceutical and biotechnology industry along the drug development process by using the radioactive tracer in non-clinical studies (ADME/PK) and bioanalyses (immunoassays).
Our services include:
- Custom Radiolabelling (177Lu, 90Y, 111In, 225Ac, 161Tb...)
- In vitro assays
- In vivo ADME/PK
- Radiopharmaceuticals services
Radiolabeling, In vitro bioanalyses, in vivo ADME/PK, and R&D support in Radiopharmaceuticals
Reliable partner for reliable molecules
Chelatec is a client oriented Contract Research Organization (CRO) specializing in radioactive labelling and preclinical investigations.
Our mission is to assist the pharmaceutical and biotechnology industry along the drug development process by using the radioactive tracer in non-clinical studies (ADME/PK) and bioanalyses (immunoassays).
Our services include:
- Custom Radiolabelling (177Lu, 90Y, 111In, 225Ac, 161Tb...)
- In vitro assays
- In vivo ADME/PK
- Radiopharmaceuticals services
Chelatec is specialized in radioactive labelling and preclinical investigations. We assist pharmaceutical and biotechnology industry along the drug development process.
Catalyst | Type | Tweets | Articles | |
---|---|---|---|---|
![]() Région Pays de la Loire National and local authorities, Government Administration | Région Pays de la Loire National and local authorities, Government Administration | Other 16 Jun 2025 | | |
![]() Atlanpole Biotherapies Public business cluster, Biotechnology, French Cluster, Biotechnology Research | Atlanpole Biotherapies Public business cluster, Biotechnology, French Cluster, Biotechnology Research | Other 2 Apr 2025 | |